natgillin/translations-raw huggingface dataset:
120 ml/min), hvilket indikerer nogen aktivitet i renal udskillelse.
120 mL/min), suggesting some active renal excretion.
120 ml:  22 kg legemsvægt
120 ml:  22 kg BW
120 opløselige tabletter
120 soluble tablets
120 patienter blev randomiseret til at få et modficeret XELIRI-regime med capecitabin (800 mg/m2 2 gange dagligt i to uger efterfulgt af 7 dages pause), irinotecan (200 mg/m2 som infusion over 30 minutter på dag 1 hver tredje uge) og bevacizumab (7,5 mg/kg som infusion over 30 til 90 minutter på dag 1 hver tredje uge).
120 Patients were randomised to a modified XELIRI regimen with capecitabine 800 mg/m2 twice daily for two weeks followed by a 7-day rest period), irinotecan (200 mg/m2 as a 30 minute infusion on day 1 every 3 weeks), and bevacizumab (7.5 mg/kg as a 30 to 90 minute infusion on day 1 every 3 weeks ;
120 pust
120 sprays
120 tabletter
120 tablets.
120 tabletter (3 x 40 tabletter)
120 tablets
120 tabletter: EU/1/09/579/010
120 tablets: EU/1/09/579/010
120 tabletter: EU/1/09/579/016
120 tablets: EU/1/09/579/016
120 tabletter: EU/1/09/580/004
120 tablets: EU/1/09/580/004
120 tabletter: EU/1/09/580/010
120 tablets: EU/1/09/580/010
120 tabletter: EU/1/09/580/016
120 tablets: EU/1/09/580/016
120 tyggetabletter
120 chewable tablets
120 x 1 filmovertrukne tabletter
120 x 1 film-coated tablets
120 x 1 kapsler
120 x 1
120 x 1 tabletter (enhedsdosis)
120x1 tablets (unit dose)
120 x 1 tabletter (enkeltdosis)
120 x 1 tablets (unit dose)
120,6 mg (S)- methopren, 160 mg amitraz
120.6 mg (S)- methoprene, 160 mg amitraz
120-139,9 kg
120 to 139.9 kg
1200 Brussels Belgien
1200 Brussels Belgium
1200 IE
1200 IU
1200 IE*** human von Willebrand-faktor** (VWF)
1200 IU*** human von Willebrand factor** (VWF)
1200 IE*** human von Willebrand-faktor** (VWF)
1200 IU*** human von Willebrand factor** (VWF).
120x1 tabletter
120x1 tablets
121 (100; 142)
Parameter
121,3 ± 5,6 ml/min/1,73 m2 i denne delgruppe, og disse eGFR'er stabiliserede sig inden for normalområdet i løbet af 4 års behandling med Replagal 0,2 mg/kg.
5.6 mL/min/1.73 m2 in this subgroup and these eGFRs stabilized in the normal range during 4 years of Replagal 0.2 mg/kg therapy, as did the eGFRs of the non-hyperfiltrators.
1210 Wien Østrig
1210 Vienna AUSTRIA
1211 Vienna Østrig
1211 Vienna Austria
1221 Wien Østrig
1221 Vienna Austria
123 (103; 144)
Sensitivity score (GSS) §
123 51 Athen Grækenland.
123 51 Athens, Greece
123 51 Athen Grækenland.
123 51 Athens, Greece.
123 dage
123 days
12489 Berlin Tyskland
12489 Berlin Germany
125 doser (250 ml).
125 doses (250 ml).
125 IE/ml efter rekonstitution)
125 IU/ml after reconstitution)
125 mg kapslen er ugennemsigtig med hvid kerne og lyserød kappe med "462" og "125 mg" præget med sort blæk på kapslen.
The 125 mg hard capsule is opaque with a white body and pink cap with “462” and “125 mg” printed radially in black ink on the body.
125 mg kapslerne er ugennemsigtige med hvid kerne og lyserød kappe med "462" og "125 mg" præget med sort blæk på den ene halvdel af kapslen.
The 125 mg capsule is opaque with a white body and pink cap with “462” and “125 mg” printed radially in black ink on the body.
125 mg optrækningsmængde
125 mg retrievable
125 mg to gange dagligt
125 mg b.i.d.
125 mg/31,25 mg/200 mg eller 150 mg/37,5 mg/200 mg eller 175 mg/43,75 mg/200 mg)-tabletter, bør doseringen af Stalevo omhyggeligt titreres til et optimalt klinisk respons.
150 mg/37.5 mg/200 mg or 175 mg/43.75 mg/200 mg) tablets, Stalevo dosing should be carefully titrated for optimal clinical response.
125 mg/31,25 mg/200 mg eller 150 mg/37,5 mg/200 mg, må du ikke tage mere end 10 tabletter pr. dag.
100 mg/25 mg/200 mg, 125 mg/31.25 mg/200 mg or 150 mg/37.5 mg/200 mg tablets, do not take more than 10 tablets per day.
125 mg/31,25 mg/200 mg eller 175 mg/43,75 mg/200 mg eller 200 mg/50 mg/200 mg)-tabletter, bør doseringen af Stalevo omhyggeligt titreres til et optimalt klinisk respons.
175 mg/43.75 mg/200 mg or 200 mg/50 mg/200 mg) tablets, Stalevo dosing should be carefully titrated for optimal clinical response.
125 mg/31,25 mg/200 mg og 150 mg/37,5 mg/200 mg.
100 mg/25 mg/200 mg, 125 mg/31.25 mg/200 mg and 150 mg/37.5 mg/200 mg.
125 ml infusionspose
125 ml infusion bag
125 ml pr. pose
125 ml per bag
125 ml – 5 år
125 ml - 5years
125 t) og hos personer med moderat nedsat leverfunktion (295 t vs.
125 h) and moderately impaired (295 h vs.
125,3 – 130,0
125.3 to 130.0
126 (107; 144)
Placebo + OBT
126 kapsler
126 capsules
127
Yes No
127 patienter blev randomiseret til behandling med capecitabin (1.000 mg/m2 2 gange dagligt i to uger efterfulgt af 7 dages pause), oxaliplatin (130 mg/m2 som infusion over 2 timer på dag 1 hver tredje uge) og bevacizumab (7,5 mg/kg som infusion over 30 til 90 minutter på dag 1 hver tredje uge).
127 patients were randomised to treatment with capecitabine (1000 mg/m2 twice daily for two weeks followed by a 7-day rest period), oxaliplatin (130 mg/m2 as a 2 hour infusion on day 1 every 3 weeks), and bevacizumab (7.5 mg/kg as a 30 to 90 minute infusion on day 1 every 3 weeks).
127,5 og 162,6 timer og 101,3 og 131,9 timer.
131.9 hours respectively.
128 dage (docetaxel alene).
128 days (docetaxel alone).
128 infusionsrelaterede reaktioner indberettet for 21 ud af 32 patienter efter indgivelse af i alt 1.612 infusioner.
128 infusion-related reactions were reported in 21 out of 32 patients following administration of a total of 1612 infusions.
12h: 6,58 ± 3,18 ng h/ml).
AUC0-12h: 6.58 ± 3.18 ng·h/ml).
12–24 måneders booster
12 Month Booster
12–24 måneders booster
12 – 24 months booster
13
Common
13 % (w/w) ethanol 95 % (se punkt 2) i vand til injektionsvæsker
13% (w/w) ethanol 95% (see section 2) in water for injections.
13 % af cirkulerende saquinavir i plasma fandtes som uomdannet aktivt stof efter oral indgift og resten som metabolitter.
13 % of circulating saquinavir in plasma was present as unchanged compound after oral administration and the remainder as metabolites.
13 (1,98 %) 20 (3,13 %) 1,15 % 35 %c
c p-value=0.22
13 (3,5)
Very common
13 Efter kortvarig behandling (gennemsnitlig varighed 22 dage) var øget vægt ≥ 7 % af baseline legemsvægt (kg) meget almindelig (40,6 %), ≥ 15 % af baseline legemsvægt var almindelig (7,1 %) og ≥ 25 % var almindelig (2,5 %).
13 Following short term treatment (median duration 22 days), weight gain ≥ 7 % of baseline body weight (kg) was very common (40.6 %), ≥ 15 % of baseline body weight was common (7.1 %) and ≥ 25 % was common (2.5 %).
13 Efter kortvarig behandling (gennemsnitlig varighed 22 dage) var øget vægt ≥ 7 % af baseline legemsvægt (kg) meget almindelig (40,6 %), ≥ 15 % af baseline legemsvægt var almindelig (7,1 %) og ≥ 25% var almindelig (2,5 %).
13 Following short term treatment (median duration 22 days), weight gain ≥ 7 % of baseline body weight (kg) was very common (40.6 %), ≥ 15 % of baseline body weight was common (7.1 %) and ≥ 25 % was common (2.5 %).
13 Efter kortvarig behandling (gennemsnitlig varighed 22 dage), var øget vægt ≥ 7 % af baseline legemsvægt (kg) meget almindelig (40,6 %), ≥ 15 % af baseline legemsvægt var almindelig (7,1 %) og ≥ 25% var almindelig.
13 Following short term treatment (median duration 22 days), weight gain ≥ 7 % of baseline body weight (kg) was very common (40.6 %), ≥ 15 % of baseline body weight was common (7.1 %) and ≥ 25 % was common (2.5 %).
13 Efter kortvarig behandling (gennemsnitlig varighed 22 dage), var øget vægt ≥ 7 % af baseline legemsvægt (kg) meget almindelig (40,6%), ≥ 15 % af baseline legemsvægt var almindelig (7,1%) og
13 Following short term treatment (median duration 22 days), weight gain ≥ 7 % of baseline body weight (kg) was very common (40.6 %), ≥15 % of baseline body weight was common (7.1 %) and
13 EVENTUELLE SÆRLIGE FORHOLDSREGLER VED BORTSKAFFELSE AF UBRUGTE LÆGEMIDLER ELLER AFFALD FRA SÅDANNE
SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCT OR WASTE MATERIALS, IF ANY
13 kapsler
13 capsules
13 kapsler, hårde
13 hard capsules
13 mg pr. dag ved baseline.
13 mg per day.
13 mg/ml benzylalkohol i vand til injektionsvæsker
13 mg/ml benzyl alcohol in water for injections.
13 til < 15
13 to < 15
13 til under 24
13 to less than 24
13 til  15
13 to < 15
13 tilfælde af tumorlysesyndrom, kapillær lækage- syndrom eller SIRS er blevet indberettet; SIRS (2 tilfælde, som begge blev anset for alvorlige), kapillær lækage-syndrom (4 tilfælde, hvoraf 3 blev anset for at være alvorlige og relaterede) og tumorlysesyndrom (7 tilfælde, hvoraf 6 blev anset for relaterede og 3 for at være alvorlige).
Thirteen events of tumour lysis syndrome, capillary leak syndrome or SIRS have been reported; SIRS (2 events; both were considered to be serious), capillary leak syndrome (4 events; 3 of which were considered serious and related) and tumour lysis syndrome (7 events; 6 of which were considered related and 3 of which were serious).
13 – Hvis stemplet gik tilbage til sin oprindelige position, skal du skubbe det ind igen, og holde det på plads.
13 - If the plunger has moved back to its original position push it in again and hold it in place.
13% (4-22%)
13% (4 to 22%)
13% tidligere undergået kirurgi med kurativ intension eller strålebehandling og havde en stigende PSA
13% had previous curative intent surgery or radiation and a rising PSA
13, 15 måneder
13, 15 months
13,0 %
n.a.
13,1 mdr.
2.18 (1.46, 3.24); < 0.001
13,1 mm x 5,2 mm.
Approximate tablet dimensions 13.1 mm x 5.2 mm
13,1 mm x 5,2 mm.
Approximate tablet dimensions 13.1 mm x 5.2 mm.
13,3 mg/24 timer depotplaster er i øjeblikket ikke til rådighed, denne styrke kan være tillgængelig fra andre marknadsføringtilladelse indehavere.
13.3 mg/24 h transdermal patch is currently not available, this presentation may although be available from other marketing authorisation holders.
13,3 til 21,5 ml/t/kg.
21.5 ml/hr/kg.
13,4 (p = 0,7613)
13.4 (p=0.7613)
13,4 mm x 7,3 mm, elipseformede normal konvekse, hvide, filmovertrukne tabletter mærket med ”OZ” over ”20” på den ene side og ”G” på den anden side.
13.4 mm x 7.3 mm, ellipse-shaped, normal convex, white film-coated tablets debossed “OZ 20” on one side and “G” on the other side.
13,4 måneder for pemetrexed-delen og 10,6 måneder for placebodelen, hazard ratio = 0,79 (95 %-CI = 0,65-0,95; p = 0,01192).
10.6 months for the placebo arm, hazard ratio = 0.79 (95 % CI = 0.65 - 0.95, p = 0.01192).
13,4; 19,5
Overall population
13,5 hændelser/1.000 patientår versus diæt alene 20,6 hændelser/1.000 patientår, (p=0,011), og
13.5 events/1,000 patient-years versus diet alone 20.6 events/1,000 patient-years, (p=0.011), and versus the combined sulphonylurea and insulin monotherapy groups
13,5 hændelser/1.000 patientår versus diæt alene 20,6 hændelser/1.000 patientår, (p=0,011), og
7.5 events/1,000 patient-years, diet alone 12.7 events/1,000 patient-years, p=0.017
13,5 hændelser/1.000 patientår versus diæt alene 20,6 hændelser/1.000 patientår, (p=0,011), og versus den kombinerede gruppe af sulfonylurinstoffer og insulin-monoterapigruppen 18,9 hændelser/1.000 patientår (p=0,021)
13.5 events/1,000 patient-years versus diet alone 20.6 events/1,000 patient-years, (p=0.011), and versus the combined sulphonylurea and insulin monotherapy groups
13,5 hændelser/1.000 patientår versus diæt alene 20,6 hændelser/1.000 patientår, (p=0,011), og versus den kombinerede sulfonylurinstof/insulinmonoterapigruppe
13.5 events/1,000 patient-years versus diet alone 20.6 events/1,000 patient-years, (p=0.011), and versus the combined sulphonylurea and insulin monotherapy groups
13,5 mg to gange daglig
13.5 mg twice daily
13,6 % (1,9; 25,3)d
< 100,000
13,6 % ; 1,4 %
Secondary Tonic-Clonic
13,6 %, p<0,001).
13.6%, p<0.001).
13,6 måneder for placeboarmen, hazard ratio = 0,71, 95 % CI = 0,56-0,88; p=0,002.
13.6 months for the placebo arm, hazard ratio = 0.71 (95% CI = 0.56-0.88, p = 0.002).
13,6 måneder for placeboarmen, hazard ratio = 0,71, 95 % CI= 0,56-0,88; p=0,002.
13.6 months for the placebo arm, hazard ratio = 0.71 (95% CI = 0.56-0.88, p = 0.002).
13,7 til 15,5
13.7 to 15.5
13,8 %
NA
13,9 (12,72 til 15,64)
13.9 (12.72 to 15.64)
13- ugers studiet blev udført for at bekræfte at ændring i administrationsvejen og anvendelsen af det nye hjælpestof rekombinant human hyalorunidase (rHuPH20) ikke påvirkede Herceptins sikkerhedsprofil.
The 13- week study was performed to confirm that the change in route of administration and the use of the novel excipient recombinant human hyaluronidase (rHuPH20) did not have an effect on the Herceptin safety characteristics.
13-19 timer.
13-19 hours.
13.970 og 2.970 ng•t/ml ved steady state.
13,970 and 2,970 ng•h/mL, respectively.
13/11l
13/ 11l
130 filmovertrukne tabletter
130 film-coated tablets
130 mg/m2 intravenøs
130 mg/m2
130 patienter (≥ 18 år) med myelomatose, som tidligere havde haft mindst partielt respons på et VELCADE-holdigt regime, fik ny behandling ved progression.
One hundred and thirty patients (≥ 18 years of age) with multiple myeloma who previously had at least partial response on a VELCADE-containing regimen were retreated upon progression.
130 tabletter
130 tablets
130 tabletter
175 tablets
1300 Wavre Belgien
1300 Wavre Belgium
131 dage
131 days
1312 og 121 patienter som fik henholdsvis 100 mg/m2 og 75 mg/m2 af docetaxel som enkeltstof.
1312 and 121 patients who received 100 mg/ m2 and 75 mg/m2 of docetaxel as a single agent respectively.
1312 og 121 patienter som fik henholdsvis 100 mg/m2 og 75 mg/m2 af docetaxel som enkeltstof.
1312 and 121 patients who received 100 mg/m2 and 75 mg/m2 of docetaxel as a single agent respectively.
1312 og 121 patienter, som fik henholdsvis 100 mg/m2 og 75 mg/m2 af doceraxel som enkeltstof.
1312 and 121 patients who received 100 mg/m2 and 75 mg/m2 of docetaxel as a single agent respectively.
1312 og 121 patienter, som fik henholdsvis 100 mg/m2 og 75 mg/m2 af doceraxel som enkeltstof.
1312 and 121 patients who received 100 mg/m² and 75 mg/m² of docetaxel as a single agent respectively.
1312 og 121 patienter, som fik henholdsvis 100 mg/m2 og 75 mg/m2 docetaxel som enkeltstof.
1312 and 121 patients who received 100 mg/m² and 75 mg/m² of docetaxel as a single agent respectively.
1312 og 121 patienter, som fik henholdsvis 100 mg/m² og 75 mg/m² af docetaxel som enkeltstof.
1312 and 121 patients who received 100 mg/m² and 75 mg/m² of docetaxel as a single agent respectively.
1316 BN Almere Nederlandene
1316 BN Almere Netherlands
1316 BN Almere Nederlandene
NL-1316 BN Almere The Netherlands‌
1316 BN, Almere Holland
1316 BN, Almere The Netherlands
132 mg (4 måleskeer) tenofovirdisoproxil (som fumarat) 33 mg/g granulat én gang dagligt anbefales.
Administration of 132 mg (4 scoops) tenofovir disoproxil (as fumarate) 33 mg/g granules once daily is recommended.
132 mikrogram (36 millioner IE)/1,5 ml.
132 micrograms (36 million IU)/1.5 mL
1330 Rixensart Belgien
1330 Rixensart Belgium
1330 Rixensart, Belgien
B-1330 Rixensart, Belgium
13342 Berlin Tyskland
13342 Berlin Germany
13342 Berlin Tyskland
D-13342 Berlin Deutschland
13353 Berlin Tyskland
13353 Berlin Germany
134 dage
134 days
13435 Berlin Tyskland
13435 Berlin Germany
135 mikrog/0,5 ml
135 mcg/0.5 ml
135 mikrog/1 ml
135 mcg/1 ml
135 mikrogram/1 ml
135 micrograms/1 ml
135 µg
injection
135 g FYLDT INJEKTIONSSPRØJTE
135 g PRE-FILLED SYRINGE
135 g FYLDT PEN
135 g PRE-FILLED PEN
135 g HÆTTEGLAS
135 g VIAL
13581 Berlin Tyskland
13581 Berlin Germany
136,0 mg/tablet
136.0 mg/tablet
137
Total TC
137,5 ml (eller 150 ml)*
137.5 ml (or 150 ml)
1379 µg/l til 1146 µg/l med deferoxamin monoterapi, p<0.001), signifikant større reduktion i myokardial jernophobning bedømt ved en stigning i MRI T2* (11,7 ms til 17,7 ms med samtidig terapi vs.
1379 µg/l to 1146 µg/l with deferoxamine monotherapy, p<0.001), significantly greater reduction in myocardial iron overload, as assessed by an increase in MRI T2* (11.7 ms to 17.7 ms with concurrent therapy vs.
1379 µg/l til 1146 µg/l med deferoxamin monoterapi, p<0.001), signifikant større reduktion i myokardial jernophobning som vurderet ved en stigning i MRI T2* (11,7 ms til 17,7 ms med samtidig terapi vs.
1379 µg/l to 1146 µg/l with deferoxamine monotherapy, p<0.001), significantly greater reduction in myocardial iron overload, as assessed by an increase in MRI T2* (11.7 ms to 17.7 ms with concurrent therapy vs.
138 patienter (29 % fik tidligere kemoterapi), og den anden var en randomiseret aktiv-kontrolleret undersøgelse med TMZ versus procarbazin hos i alt 225 patienter (67 % fik tidligere behandling med nitrosurea-baseret kemoterapi).
One was a non-comparative trial in 138 patients (29% received prior chemotherapy), and the other was a randomised active-controlled trial of TMZ vs procarbazine in a total of 225 patients (67% received prior treatment with nitrosourea based chemotherapy).
138 patienter (29 % fik tidligere kemoterapi), og den anden var en randomiseret aktiv-kontrolleret undersøgelse med TMZ versus procarbazin hos i alt 225 patienter (67 % fik tidligere behandling med nitrosurea-baseret kemoterapi).
One was a non-comparative trial in 138 patients (29% received prior chemotherapy), and the other wasa randomised active-controlled trial of TMZ vs procarbazine in a total of 225 patients (67% received prior treatment with nitrosourea based chemotherapy).
1381 Weesp Holland
1381 CP Weesp The Netherlands
139 t), sammenlignet med matchede raske personer.
139 h) subjects compared to matched healthy subjects.
13C og urea er uskadelige, naturligt forekommende stoffer, som findes i kroppen.
13C and urea are harmless naturally occurring substances which are found in your body.
13C/12C-forholdet i en vilkårlig CO2-koncentration over 1 %.
13C/12C-ratio at any CO2 concentration above 1 %.
13Efter kortvarig behandling (gennemsnitlig varighed 22 dage), var øget vægt ≥ 7 % af baseline legemsvægt (kg) meget almindelig (40,6 %), ≥ 15 % af baseline legemsvægt var almindelig (7,1%) og
13 Following short term treatment (median duration 22 days), weight gain ≥ 7 % of baseline body weight (kg) was very common (40.6 %), ≥ 15 % of baseline body weight was common (7.1 %) and
13legemsvægt (kg) meget almindelig (40,6 %), ≥ 15 % af baseline legemsvægt var almindelig (7,1%) og ≥ 25 % var almindelig (2,5 %).
13 Following short term treatment (median duration 22 days), weight gain ≥ 7 % of baseline body weight (kg) was very common (40.6 %), ≥ 15 % of baseline body weight was common (7.1 %) and ≥ 25 % was common (2.5 %).
13ème rue – L.I.D – BP 27 F-06517 Carros
1ère avenue 2065 m – L.I.D F-06516 Carros
14 (18,2 %)
All nails clearedc
14 - 28 - 56 - 84 - 98 tabletter: Ma
14 - 28 - 56 - 84 - 98 tablets:
14 - 28 - 56 - 98 tabletter:
14 - 28 - 56 - 98 tablets:
14 - Smid hætteglasset og den ubrugte del af opløsningen i affaldsbeholderen.
14 - Dispose of the vial and the remaining unused portion of the solution into the disposal unit.
14 De observerede normalniveauer ved baseline (< 1,016 mmol/l ved faste) steg til høje niveauer (≥ 1,467 mmol/l), og triglyceridniveauerne ved faste, der lå ved grænsen ved baseline (≥ 1,016 mmol/l
14 Observed for fasting normal levels at baseline (< 1.016 mmol/l) which increased to high (≥ 1.467 mmol/l) and changes in fasting triglycerides from borderline at baseline (≥ 1.016 mmol/l
14 depottabletter - EU/1/07/395/069 - HVIDE 28 depottabletter - EU/1/07/395/026- HVIDE 30 depottabletter - EU/1/07/395/027 - HVIDE 49 depottabletter - EU/1/07/395/028- HVIDE 56 depottabletter - EU/1/07/395/029 - HVIDE 98 depottabletter - EU/1/07/395/030 - HVIDE
14 prolonged-release tablets - EU/1/07/395/069 - WHITE 28 prolonged-release tablets - EU/1/07/395/026 - WHITE 30 prolonged-release tablets - EU/1/07/395/027 - WHITE 49 prolonged-release tablets - EU/1/07/395/028 - WHITE 56 prolonged-release tablets - EU/1/07/395/029 - WHITE 98 prolonged-release tablets - EU/1/07/395/030 - WHITE
14 depottabletter - EU/1/07/395/072 - HVIDE 28 depottabletter - EU/1/07/395/031- HVIDE 30 depottabletter - EU/1/07/395/032 - HVIDE 49 depottabletter - EU/1/07/395/033- HVIDE 56 depottabletter - EU/1/07/395/034 - HVIDE 98 depottabletter - EU/1/07/395/035 – HVIDE
14 prolonged-release tablets - EU/1/07/395/072 - WHITE 28 prolonged-release tablets - EU/1/07/395/031 - WHITE 30 prolonged-release tablets - EU/1/07/395/032 - WHITE 49 prolonged-release tablets - EU/1/07/395/033 - WHITE 56 prolonged-release tablets - EU/1/07/395/034 - WHITE 98 prolonged-release tablets - EU/1/07/395/035 - WHITE
14 depottabletter - EU/1/07/395/074 - KLARE 28 depottabletter - EU/1/07/395/016 - KLARE 30 depottabletter - EU/1/07/395/017- KLARE 49 depottabletter - EU/1/07/395/018- KLARE 56 depottabletter - EU/1/07/395/019- KLARE 98 depottabletter - EU/1/07/395/020- KLARE
14 prolonged-release tablets - EU/1/07/395/074 - CLEAR 28 prolonged-release tablets - EU/1/07/395/016 - CLEAR 30 prolonged-release tablets - EU/1/07/395/017 - CLEAR 49 prolonged-release tablets - EU/1/07/395/018 - CLEAR 56 prolonged-release tablets - EU/1/07/395/019 - CLEAR 98 prolonged-release tablets - EU/1/07/395/020 - CLEAR
14 depottabletter - EU/1/07/395/077 - KLARE 28 depottabletter - EU/1/07/395/078 - KLARE 30 depottabletter - EU/1/07/395/079- KLARE 49 depottabletter - EU/1/07/395/080- KLARE 56 depottabletter - EU/1/07/395/081- KLARE 98 depottabletter - EU/1/07/395/082- KLARE
14 prolonged-release tablets - EU/1/07/395/077 - CLEAR 28 prolonged-release tablets - EU/1/07/395/078 - CLEAR 30 prolonged-release tablets - EU/1/07/395/079 - CLEAR 49 prolonged-release tablets - EU/1/07/395/080 - CLEAR 56 prolonged-release tablets - EU/1/07/395/081 - CLEAR 98 prolonged-release tablets - EU/1/07/395/082 – CLEAR
14 depottabletter - EU/1/07/395/083 - HVIDE 28 depottabletter - EU/1/07/395/084- HVIDE 30 depottabletter - EU/1/07/395/085 - HVIDE 49 depottabletter - EU/1/07/395/086- HVIDE 56 depottabletter - EU/1/07/395/087 - HVIDE 98 depottabletter - EU/1/07/395/088 - HVIDE
14 prolonged-release tablets - EU/1/07/395/083 - WHITE 28 prolonged-release tablets - EU/1/07/395/084 - WHITE 30 prolonged-release tablets - EU/1/07/395/085 - WHITE 49 prolonged-release tablets - EU/1/07/395/086 - WHITE 56 prolonged-release tablets - EU/1/07/395/087 - WHITE 98 prolonged-release tablets - EU/1/07/395/088 - WHITE
14 depottabletter EU/1/07/395/071 - KLARE 28 depottabletter - EU/1/07/395/011 - KLARE 30 depottabletter - EU/1/07/395/012- KLARE 49 depottabletter - EU/1/07/395/013- KLARE 56 depottabletter - EU/1/07/395/014- KLARE 98 depottabletter - EU/1/07/395/015- KLARE
14 prolonged-release tablets - EU/1/07/395/071 - CLEAR 28 prolonged-release tablets - EU/1/07/395/011 - CLEAR 30 prolonged-release tablets - EU/1/07/395/012 - CLEAR 49 prolonged-release tablets - EU/1/07/395/013 - CLEAR 56 prolonged-release tablets - EU/1/07/395/014 - CLEAR 98 prolonged-release tablets - EU/1/07/395/015 - CLEAR
14 enterokapsler hårde
14 gastro-resistant hard capsules
14 enterotabletter
14 gastro-resistant tablets
14 filmovertrukne tabeltter.
14 Film-coated tablets
14 filmovertrukne tabletter
14 film--coated tablets
14 filmovertrukne tabletter (kalenderpakning)
14 film-coated tablets (calendar blister)
14 filmovertrukne tabletter 28 filmovertrukne tabletter 30 filmovertrukne tabletter 42 filmovertrukne tabletter 50 filmovertrukne tabletter 56 filmovertrukne tabletter 60 filmovertrukne tabletter 70 filmovertrukne tabletter 84 filmovertrukne tabletter 90 filmovertrukne tabletter 98 filmovertrukne tabletter 100 filmovertrukne tabletter
14 film-coated tablets 28 film-coated tablets 30 film-coated tablets 42 film-coated tablets 50 film-coated tablets 56 film-coated tablets 60 film-coated tablets 70 film-coated tablets 84 film-coated tablets 90 film-coated tablets 98 film-coated tablets 100 film-coated tablets
14 filmovertrukne tabletter 7 filmovertrukne tabletter
14 film-coated tablets 7 film-coated tablets
14 filmovertrukne tabletter [28 filmovertrukne tabletter] [56 filmovertrukne tabletter] [84 filmovertrukne tabletter] [98 filmovertrukne tabletter] [100 filmovertrukne tabletter]
14 film-coated tablets [28 film-coated tablets] [56 film-coated tablets] [84 film-coated tablets] [98 film-coated tablets] [100 film-coated tablets]
14 filmovertrukne tabletter i kalenderblistere
14 film-coated tablets in calendar blisters
14 filmovertrukne tabletter.
14 Film-coated tablets
14 filmovertrukne tabletter.
14 Film-coated tablets.